OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its ...
OmniAb, Inc. operates within the biotechnology sector, focusing on pioneering therapeutic antibody discovery. The company's core offering is a comprehensive platform that enables pharmaceutical and biotech partners to access a broad spectrum of antibody repertoires and employ sophisticated screening techniques. This facilitates the development of next-generation treatments. Central to OmniAb's ...OmniAb, Inc. operates within the biotechnology sector, focusing on pioneering therapeutic antibody discovery. The company's core offering is a comprehensive platform that enables pharmaceutical and biotech partners to access a broad spectrum of antibody repertoires and employ sophisticated screening techniques. This facilitates the development of next-generation treatments. Central to OmniAb's technology are proprietary genetically engineered animals, including OmniRat, OmniChicken, and OmniMouse, which are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, the company offers specialized technologies such as OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) for bispecific antibody applications via a common light chain method, and OmniTaur, which leverages the unique structural properties of cow antibodies for challenging targets. Founded in 2012 and headquartered in Emeryville, California, OmniAb was spun off from Ligand Pharmaceuticals in November 2022. As of the latest data, the company has approximately 114 full-time employees. Financially, OmniAb generates revenue through licensing its discovery technology to partners, with a gross profit margin of about 50.5% and a revenue per share of $0.298. The company invests heavily in research and development, with R&D expenses amounting to 113.1% of revenue, reflecting its innovative focus. Key executives include CEO Matthew W. Foehr, who brings over 25 years of pharmaceutical industry experience. OmniAb's platform has contributed to over 280 programs and three product approvals, and the company continues to expand its partnerships, entering into six new license agreements in the second quarter of 2025. The company's strategic vision is to address the growing discovery needs of the global pharmaceutical industry with an efficient, customizable, end-to-end solution, positioning itself as a leader in antibody discovery.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$18.7M
-29.3%
-6.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-64.8M
-4.4%
+23.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-18.2%
-118.2%
+63.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-383.1%
-35.7%
+9.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-347.0%
-47.6%
+18.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-37.0M
+10.9%
+150.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-198.3%
-26.0%
+154.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
7.6%
-5.4%
-3.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.02x
-11.0%
-0.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good afternoon, and welcome to OmniAb Inc.'s Second Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Kurt Gustafson, OmniAb Inc.'s Chief Financial Officer. You may begin. Thank you.
Kurt Gustafson: Thank you, operator, and good afternoon, everyone. Thank you all for joining our second quarter 2026 financial results conference call. There are slides to accompany today's prepared remarks, and they're available in the Investor section of our website at omniab.com. Before we begin, I'd like to remind listeners that comments made during this call by OmniAb's management will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any anticipated results. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, today, August 6, 2026. Except as required by law, OmniAb undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Joining me on the call this afternoon is Matt Foehr, OmniAb's President and CEO, as well as Amechi Nwachuku, our recently appointed Chief Operating Officer. During today's call, Matt is going to cover some business highlights, and I'll review our Q2 financial results and update our full year guidance, and then we'll open the call to questions. And with that, let me turn the call over to Matt.
Matthew Foehr: Thanks, Kurt. Good afternoon, everyone, and thanks for joining our second quarter call. I'll start now on Slide #4. We continue to see momentum in the business with the second quarter's strong performance led by advancements in our portfolio of partner programs. Our business here at OmniAb has been designed to benefit from long-term and durable revenue streams. We're excited to report that the programs derived from our differentiated discovery technologies continue to move into the clinic and to make progress through later-stage clinical development. This clinical progression gives visibility into the value that can be realized as our pipeline matures and as an increasing number of partnered programs reach milestones and approach potential royalty generation. Our novel technologies reinforce our position as a key enabling technology licensing partner and support both existing and new partnerships. Novel differentiated technologies and our capabilities keep us at the forefront of next-generation discovery, enabling meaningful value creation for our stakeholders and the broader industry. We're pleased to note that both of our most recently launched …
